国产精品久久久_欧美日韩中文国产一区_日本高清Aⅴ免费网站_亚洲制服精品无码中文

[China Chemical Instrument Network Famous Enterprise News] GE Healthcare provides a production platform based on bioprocess one-time technology, advanced processing automation and compact clean room structure, which can help customers quickly configure cGMP production capacity. Compared with traditional facilities, the one-time production platform greatly reduces the construction cost and cycle, helps accelerate the process of developing drugs into clinical and commercial production, and enhances the partner's production capacity and ability to cope with risks.

On April 18, 2017, GE Healthcare and Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Bai Li Pharmaceutical”) held a signing ceremony in Chengdu to jointly announce the Chengdu Dot-Ter antibody drug under the Baili Pharmaceutical Company. The limited liability company (hereinafter referred to as “Dote antibody”) adopts the biopharmaceutical production line of GE Medical One-Time Technology Platform, and builds the first advanced antibody drug production base in Chengdu that meets the Chinese, American and European GMP standards, and is completed and put into production.

Dot's antibody is based on GE's one-time biopharmaceutical production line. Based on the production of innovative monoclonal antibodies, multi-specific antibodies, and antibody-conjugated drugs (ADC), Dot-Pro antibody will become the first antibody drug in Chengdu Medical City Industrial Park. pharmacy company. The innovative development of Baili Pharmaceutical's antibody drugs will drive the introduction of high-end talents and advanced projects in the industrial park, as well as the formation of the antibody drug industry chain, thereby promoting the upgrading of the bio-pharmaceutical industry in Chengdu and even in the southwest. In recent years, China has vigorously supported the development of the biomedical industry. As one of China's seven emerging strategic industries, the biopharmaceutical industry has become the focus of China's high-tech development. In Chengdu, the biomedical industry is at the forefront of the key development industry directory. Zhu Yi, chairman of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. said: “‘To make patients healthy and energetic” has always been one of the core values ??of Baili Pharmaceutical.

We have always built a diversified and leading research product line in the field of tumor antibody drugs through a strong R&D platform for sustainable innovation and a Chinese and foreign R&D team. With GE Healthcare's flexible biopharmaceutical production platform based on biotechnology one-off technology, we will build a first-class biopharmaceutical production base in China, and accelerate the production of higher quality and more affordable innovative antibodies to patients with higher productivity. Drugs, and with rich service and technology output, drive the overall development of bio-pharmaceuticals in industrial parks and even in Southwest China. GE Healthcare's production platform based on bioprocess disposable technology, advanced processing automation and compact clean room structure can help customers quickly deploy cGMP production capacity. Compared with traditional facilities, one-time production platform greatly reduces construction costs and The cycle helps accelerate the process of developing drugs into clinical and commercial production, and enhances the partner's production capacity and ability to cope with risks. During the construction period, GE Healthcare strictly follows the cGMP guidelines and actively works for workshop construction, equipment manufacturing, installation and commissioning, and personnel. Training and other technical support and services were provided. Mr. Li Qing, General Manager of GE Medical Life Science Division, said: “GE Healthcare and Bailey Pharmaceuticals are all companies that focus on 'innovation'. As a long-term partner of China's biopharmaceutical companies, we are always helping innovative R&D and production of biopharmaceutical companies with innovative technologies and solutions, while Pali Pharmaceuticals is driving the advancement of companies and industries through innovative drug research and development. The cooperation between the two sides will fully bring together the power of ‘innovation’ and let the acceleration of innovation benefit more patients. ”

It is reported that the innovative tumor antibody drug production base based on GE's one-off technology platform was officially started in October 2016 and put into operation on April 18, 2017.

Edit review

Nowadays, GE Healthcare has been involved in the continuous development of biopharmaceutical production lines. GE Healthcare has formed a biopharmaceutical industry chain development model with the help of biotechnology, and will continue to inject its own R&D technology in clinical medicine, biomedicine, and antibody drugs in the future. .

(Original title: GE Healthcare "One-off Technology" to help upgrade the biopharmaceutical industry in Southwest China) (Source: GE Healthcare)